Nuveen Asset Management LLC Lowers Stock Holdings in Encompass Health Co. (NYSE:EHC)

Nuveen Asset Management LLC lessened its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 4.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 529,201 shares of the company's stock after selling 23,866 shares during the period. Nuveen Asset Management LLC owned about 0.53% of Encompass Health worth $48,872,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB grew its holdings in Encompass Health by 87.8% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after purchasing an additional 137 shares during the period. Colonial Trust Co SC bought a new stake in shares of Encompass Health during the fourth quarter worth approximately $29,000. Transce3nd LLC bought a new stake in shares of Encompass Health during the fourth quarter worth approximately $40,000. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Encompass Health by 38.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after acquiring an additional 127 shares during the period. Finally, V Square Quantitative Management LLC boosted its holdings in shares of Encompass Health by 43.8% during the fourth quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock worth $54,000 after acquiring an additional 177 shares during the period. Institutional investors own 97.25% of the company's stock.

Encompass Health Stock Up 0.1%

Shares of EHC traded up $0.13 on Friday, hitting $118.74. The company's stock had a trading volume of 388,011 shares, compared to its average volume of 699,207. The firm's fifty day moving average price is $107.85 and its 200-day moving average price is $101.40. Encompass Health Co. has a fifty-two week low of $82.74 and a fifty-two week high of $121.96. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $11.97 billion, a price-to-earnings ratio of 26.62, a P/E/G ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.12 earnings per share. On average, equities research analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date is Tuesday, July 1st. Encompass Health's payout ratio is 14.05%.

Analyst Ratings Changes

Several analysts recently weighed in on EHC shares. Wall Street Zen raised shares of Encompass Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday. William Blair reissued an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. KeyCorp raised their target price on shares of Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Barclays raised their target price on shares of Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, UBS Group upped their target price on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a report on Monday, April 28th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $120.86.

Insider Buying and Selling

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now directly owns 527,070 shares of the company's stock, valued at approximately $64,054,817.10. This trade represents a 18.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the transaction, the insider now directly owns 11,958 shares of the company's stock, valued at approximately $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 132,663 shares of company stock valued at $16,034,082. 2.00% of the stock is owned by insiders.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.